First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

por Weiss, Glen J., Chao, Joseph, Neidhart, Jeffrey D., Ramanathan, Ramesh K., Bassett, Dawn, Neidhart, James A., Choi, Chung Hang J., Chow, Warren, Chung, Vincent, Forman, Stephen J., Garmey, Edward, Hwang, Jungyeon, Kalinoski, D. Lynn, Koczywas, Marianna, Longmate, Jeffrey, Melton, Roger J., Morgan, Robert, Oliver, Jamie, Peterkin, Joanna J., Ryan, John L., Schluep, Thomas, Synold, Timothy W., Twardowski, Przemyslaw, Davis, Mark E., Yen, Yun
Publicado 2013

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

por Lang, Frederick F., Conrad, Charles, Gomez-Manzano, Candelaria, Yung, W.K. Alfred, Sawaya, Raymond, Weinberg, Jeffrey S., Prabhu, Sujit S., Rao, Ganesh, Fuller, Gregory N., Aldape, Kenneth D., Gumin, Joy, Vence, Luis M., Wistuba, Ignacio, Rodriguez-Canales, Jaime, Villalobos, Pamela A., Dirven, Clemens M.F., Tejada, Sonia, Valle, Ricardo D., Alonso, Marta M., Ewald, Brett, Peterkin, Joanna J., Tufaro, Frank, Fueyo, Juan
Publicado en J Clin Oncol (2018)